Allen Operations’s Recursion Pharmaceuticals RXRX Stock Holding History

Allen Operations’s Portfolio RXRX Stock Details RXRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$799K	Hold	217,657	–	–	0.11%	29
2026 Q1	$668K	Hold	217,657	–	–	0.1%	32
2025 Q4	$890K	Hold	217,657	–	–	0.11%	33
2025 Q3	$1.06M	Hold	217,657	–	–	0.13%	32
2025 Q2	$1.1M	Hold	217,657	–	–	0.15%	29
2025 Q1	$1.15M	Hold	217,657	–	–	0.19%	24
2024 Q4	$1.47M	Hold	217,657	–	–	0.23%	25
2024 Q3	$1.43M	Hold	217,657	–	–	0.24%	23
2024 Q2	$1.63M	Hold	217,657	–	–	0.32%	24
2024 Q1	$2.17M	Hold	217,657	–	–	0.41%	23
2023 Q4	$2.15M	Hold	217,657	–	–	0.43%	25
2023 Q3	$1.67M	Hold	217,657	–	–	0.37%	27
2023 Q2	$1.63M	Hold	217,657	–	–	0.36%	26
2023 Q1	$1.45M	Hold	217,657	–	–	0.37%	26
2022 Q4	$1.68M	Hold	217,657	–	–	0.45%	26
2022 Q3	$2.32M	Hold	217,657	–	–	0.62%	22
2022 Q2	$1.77M	Hold	217,657	–	–	0.45%	23
2022 Q1	$1.56M	Hold	217,657	–	–	0.27%	29
2021 Q4	$3.73M	Buy	217,657 +149,553	+220%	+$2.81M	0.52%	22
2021 Q3	$1.57M	Hold	68,104	–	–	0.24%	30
2021 Q2	$2.49M	Buy	+68,104	New	+$2.02M	0.43%	25

Other funds holding RXRX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

SoftBank Group Tokyo, Japan $18.2B AUM 177.65% 1-Year Est. Return

MCMU

MIC Capital Management (UK) London, United Kingdom $394M AUM 25.64% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Allen Operations's RXRX Position: Q2 2026 in Review

Allen Operations held its Recursion Pharmaceuticals (RXRX) position steady in Q2 2026 at 217,657 shares worth $799K. The position accounts for 0.11% of the portfolio, ranked #29.

Allen Operations first reported a position in RXRX in Q2 2021 and has held it in 21 quarters since. The position peaked at $3.73M in Q4 2021. 342 funds tracked by Wall St. Rank hold RXRX as of Q2 2026.

Allen Operations held 217,657 shares of Recursion Pharmaceuticals worth $799K as of Q2 2026.
Allen Operations left its Recursion Pharmaceuticals share count unchanged in Q2 2026.
Recursion Pharmaceuticals made up 0.11% of Allen Operations's portfolio in Q2 2026, its #29 holding.
Allen Operations first reported a position in Recursion Pharmaceuticals in Q2 2021 and has held it in 21 quarters since.
Allen Operations's Recursion Pharmaceuticals position peaked at $3.73M in Q4 2021.
342 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q2 2026.

Based on Allen Operations's 13F filing for Q2 2026, filed 5 Aug 2026.